Long-Term Outcomes of Children and Adolescents With Postural Tachycardia Syndrome After Conventional Treatment

Chunyan Tao\(^1\), Wenxin Lu\(^1\), Jing Lin\(^1\), Hongxia Li\(^1\), Xueying Li\(^2\), Chaoshu Tang\(^3\), Junbao Du\(^{1,4}\) and Hongfang Jin\(^{1*}\)

\(^1\) Department of Pediatrics, Peking University First Hospital, Beijing, China, \(^2\) Department of Medical Statistics, Peking University First Hospital, Beijing, China, \(^3\) Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China, \(^4\) Key Laboratory of Molecular Cardiovascular Science, The Ministry of Education, Beijing, China

Objectives: To explore the long-term outcomes of children and adolescents with postural tachycardia syndrome receiving conventional interventions.

Materials and Methods: A total of 121 patients were recruited, but 6 (5.0%) of them were lost at follow-up. The detailed clinical data were collected, and the reoccurrence and frequency of orthostatic intolerance symptoms were evaluated with a mean followed-up period of 18.7 months (range, 14–74 months). The Kaplan-Meier curve was used to show the cumulative symptom-free rate of patients over time. Factors influencing the long-term outcomes were examined using the Cox’s proportional hazards models.

Results: The cumulative symptom-free rate was gradually increased over time. It was 48.4% at the 1-year follow-up and increased to 85.6% at the 6-year follow-up. The duration of symptoms before treatment and the maximum upright heart rate in standing-up test were identified as independent indicators for the long-term outcomes. Each 1-month prolongation in the duration of symptoms before treatment was associated with a 1.2% decrease in the cumulative symptom-free rate. However, each 1-bpm increase in the maximum upright heart rate in standing-up test was associated with a 2.1% increase in the cumulative symptom-free rate.

Conclusions: The long-term outcomes of postural tachycardia syndrome patients who received conventional interventions are benign and the cumulative symptom-free rate was gradually increased over time. The prolonged duration of symptoms before treatment and the reduced maximum upright heart rate in standing-up test are the independent risk indicators.

Keywords: postural tachycardia syndrome, conventional interventions, long-term outcomes, children, adolescents
INTRODUCTION

Postural tachycardia syndrome (POTS) is an important form of orthostatic intolerance (OI) and is a constellation of symptoms including lightheadedness, chest discomfort, blurred vision, palpitations, and even syncope, which are elicited by excessive upright tachycardia and relieved by recumbency (1).

POTS in adolescents was firstly described by Bou-Holaigh et al. and it occurs at an estimated rate of 6.8% (2, 3). It negatively affects their physical and psychological health and impairs their quality of life (4, 5). Therefore, the investigation of the treatment for POTS has attracted great interest of clinical scientists. Up to now, multiple therapeutic methods have been introduced to deal with POTS in children and adolescents (6), among which conventional interventions are irreplaceable for their simplicity and for no obvious adverse effects (7, 8). There have been several studies on the therapeutic efficacy of conventional interventions in pediatric POTS patients (9–14). However, their long-term outcomes have never been reported, which limits pediatricians to predict the prognosis of this disease.

Therefore, this study focuses on the long-term outcomes and the associated factors of pediatric POTS patients receiving conventional treatment.

MATERIALS AND METHODS

We enrolled 121 patients [54 males and 67 females, median age 12.0 (10.0, 13.0) years] with a diagnosis of POTS and treated with conventional interventions at the Department of Pediatrics of Peking University First Hospital from July 2012 to July 2017. One hundred and fifteen patients completed our follow-up by telephone or clinic visits, but the remaining six patients (5.0%) were lost. This research was authorized by the Ethics Committee of Peking University First Hospital and all guardians of included patients gave written informed consent in accordance with the percepts expressed in the Declaration of Helsinki.

Mean corpuscular hemoglobin concentration and platelet were from blood routine test. Blood was drawn by venipuncture after at least 4 h fast and collected in a tube containing ethylene diamine tetraacetic acid. It was tested immediately at the Medical Laboratory of Peking University First Hospital (XE-5000, SYSMEX Corporation, Kobe, Japan) (13).

A urine collection kit for each patient was prepared in advance. A 24 h urine sample was collected and patients were asked to take the 24 h urine samples during non-menstrual days. The 24 h urinary sodium excretion was determined using the ion-selective electrode method (Cobas 6000, Roche, Switzerland). Twenty-four hours urinary sodium excretion = the concentration of sodium × the total urine volume (15).

Drugs influencing autonomic nervous function were avoided for at least 3 days before standing-up test. The testing environment was quiet, warm and dimly lit. Heart rate and blood pressure were recorded after 10–20 min of supine rest. Then, the patient was asked to stand for another 10 min, with simultaneously monitoring of heart rate and blood pressure (Dash 2000, General Electric, Schenectady, New York). The test was terminated ahead if the patient could not persist in finishing it. ΔHR = the maximum heart rate during standing—the baseline heart rate during supine (16).

Criteria of POTS in children and adolescents consisted of the following: (1) the presence of predisposing factors such as prolonged standing, rapid postural changes or exposure to emotional stress; (2) suffering from OI symptoms; (3) a positive response during standing-up test [normal heart rate in the supine position and an increment of heart rate ≥ 40 bpm or a maximum heart rate ≥ 130 bpm (in children aged 6–12 years) or ≥ 125 bpm (in adolescents aged 13–18 years) in standing-up test, without a decrease in blood pressure ≥20/10 mmHg]; and (4) the exclusion of other diseases that may likely cause OI symptoms (16).

The symptom scores of POTS were determined by the presence of typical symptoms (dizziness, headache, syncope, blurred vision, palpitation, chest discomfort, nausea, tremors, and sweating). Each symptom was counted based on its frequency (0 score, no symptom; 1 score, each symptom occurring once per month; 2 scores, 2–4 times per month; 3 scores, 2–7 times per week; 4 scores, more than once per day) and the total scores were calculated by summing all of the scores of each symptom (17).

Conventional interventions were used for each patient once diagnosed with POTS. Details of conventional interventions were listed as follows: (1) health education: informing patients and their guardians of possible causes, and teaching them how to avoid triggers and to protect themselves when experiencing OI symptoms; (2) supplement of water and salt: one bag of oral rehydration saline (Anjian Pharma Company, Xi’an, China) per day, containing 0.650 g sodium chloride, 0.725 g sodium citrate, 0.375 g potassium chloride and 3.375 g anhydrous glucose; (3) orthostatic training: asking patients to stand against a wall with the feet 15 cm away from the wall for a gradually increasing duration from 3 to 30 min, 2–3 times a day, depending on their orthostatic tolerance (11, 18). None of the patients continued implementing these interventions during the long-term follow-up. However, two of them got metoprolol or midodrine hydrochloride treatment for recurrent OI symptoms and they were regarded as censored subjects at the beginning of the introduction of the abovementioned new interventions. Designated doctors conducted the follow-up tasks by telephone or clinic visits in October 2018, with a mean follow-up duration of 18.7 months (range, 14–74 months). The main content of follow-up contained the reoccurrence and frequency of OI symptoms.

SPSS version 21.0 (IBM, Armonk, New York) was used for all data analyses. The normality of continuous data was examined by the Shapiro-Wilk test and continuous data with normal distribution are presented as mean ± standard deviation, otherwise as median (P25, P75). Bivariate correlations for continuous variables were tested using Pearson’s correlation coefficient. Categorical variables are summarized as numbers (percentages). No reoccurrence of OI symptoms during follow-up was defined “event.” The Kaplan-Meier curve was used to show the trend of cumulative symptom-free rate of patients.

Abbreviations: POTS, Postural tachycardia syndrome; OI, Orthostatic intolerance.
follow-up time. The cumulative symptom-free rates at 1, 2, 3, 4, 5, and 6 years after the beginning of follow-up were 48.4, 59.8, 73.0, 82.0, 85.6 and 85.6%, respectively.

Parameters with a \( p < 0.1 \) in the Cox univariate analysis (the duration of symptoms before treatment, the supine heart rate and the maximum heart rate in standing-up test, Table 2) were introduced in the multivariate analysis. However, given the strong collinearity between the supine heart rate and the maximum heart rate in standing-up test \( r = 0.711, 95\% CI, 0.620–0.795, p < 0.001 \) and the maximum heart rate used as one of the diagnostic criteria for POTS in standing-up test (16), only the maximum upright heart rate and the duration of symptoms before treatment were included eventually. The multivariate model showed that both of them were independent indicators for the long-term outcomes of the study patients \( p < 0.05, \) Table 3.

For each 1-month prolongation in the duration of symptoms before treatment, a decrease of 1.2% in the cumulative symptom-free rate was detected. However, for each 1-bpm acceleration in the maximum upright heart rate during standing-up test, an increase of 2.1% was detected.

**DISCUSSION**

In this research, we found that the cumulative symptom-free rate was gradually increasing during follow-up period. The duration of symptoms before treatment and the maximum upright heart rate in standing-up test were independent indicators for the long-term outcomes of pediatric POTS patients after conventional treatment, the former being a risk factor with its prolongation and the latter being a protective factor with its acceleration.

POTS is a hot topic in pediatrics, not only for its relatively high prevalence but also for its impact on the quality of life (19). We found that although most patients had benign outcomes, some of them still sustained OI symptoms for such a long term that it would be of help to reduce their psychological burden if clinicians could predict the prognosis and its influencing factors in advance. Kimpinski et al. conducted a prospective study to demonstrate favorite clinical outcomes at the 1-year follow-up, however, their therapeutic regimens were miscellaneous (20).

Prolonged duration of symptoms before treatment was identified as a risk factor for the prognosis of POTS patients receiving conventional interventions. Namely, the earlier such treatment was carried out, the better the prognosis would be. Unfortunately, in a large pediatric sample-sized study, Boris et al. observed that most of the participants visited doctors after suffering from OI symptoms for about 2 years (21), implying that the patients and their guardians might overlook such symptoms and more importantly, the physicians might lack the awareness of POTS and make misdiagnosis sometimes (22). Our results provided physicians with the evidence to encourage patients to visit doctors as early as possible and emphasized the importance of recognizing POTS.

When changing from supine to upright, gravity produces a rapid and large downward shift from thorax into vessels of the lower body. Simultaneously, the endogenous integrated

### TABLE 1 | Baseline demographic and clinical characteristics of the study participants.

| Characteristics | Values |
|-----------------|--------|
| Participants (n) | 115 |
| Age (years) | 12.0 (10.0, 13.0) |
| Gender (n, male/female) | 50/65 |
| Body mass index (kg/m²) | 17.4 (16.1, 19.8) |
| Duration of symptoms before treatment (months) | 10.5 (2.0, 36.0) |

**MEDICAL HISTORY**

| Predisposing factors (n, yes/no) | 77/38 |
| Syncope (n, yes/no) | 61/54 |
| Symptom scores before treatment (points) | 4 (3, 7) |

**PERSONAL HISTORY**

| Motion sickness (n, yes/no) | 16/99 |
| Allergic diseases (n, yes/no) | 29/86 |
| Family history about OI (n, yes/no) | 29/86 |

**CHARACTERISTICS IN STANDING-UP TEST**

| Supine heart rate (bpm) | 74 ± 11 |
| Maximum upright heart rate (bpm) | 121 ± 14 |
| Changes of heart rate (bpm) | 46 (40, 53) |

**ITEMS OF BLOOD ROUTINE TEST**

| Mean corpuscular hemoglobin concentration (g/L) | 347 (339, 354) |
| Platelet (*10⁹/L) | 257 (229, 298) |
| 24 h urinary sodium excretion (mmol/24 h) | 102 (73, 135) |
| Duration of treatment (months) | 3.5 (3.5) |

OI, orthostatic intolerance. Continuous data with normal distribution are presented as mean ± standard deviation, otherwise as median (P₂₅, P₇₅) and categorical variables are summarized as numbers.
mechanisms are activated to compensate the reduced venous return. Any abnormality in the regulated progress might result in postural tachycardia (23). Our team previously found that the maximum upright heart rate in standing-up test ≥ 123 bpm could predict a favorable outcome after oral rehydration saline therapy in pediatric POTS patients (10). Tachycardia would be more obvious when reduced blood volume and impaired muscle sympathetic nerve activity occur concurrently in POTS patients, both of which are identified as common mechanisms for POTS (24, 25). Supplement of water and salt and orthostatic training could not only increase blood volume but also improve muscle sympathetic nerve activity (10, 26, 27). Under such condition, conventional treatment might improve patients' well-being significantly. It was observed in this study that the cumulative symptom-free rate would increase by 2.1% if there was a 1-bpm acceleration in the maximum upright heart rate in standing-up test. However, body mass index, mean corpuscular hemoglobin concentration, 24 h urinary sodium excretion and platelet, reported to have correlations with blood volume or autonomic nervous function (9, 10, 12, 28), were not

### TABLE 2 | Results of univariate Cox’s proportional hazard model regression.

| Characteristics                                      | B     | SE    | Wald   | p-value | HR (95% CI)       |
|-------------------------------------------------------|-------|-------|--------|---------|------------------|
| Age (years)                                           | −0.067| 0.045 | 2.164  | 0.141   | 0.936 (0.856–1.022) |
| Gender (male vs. female)                              | −0.181| 0.221 | 0.674  | 0.412   | 0.834 (0.541–1.286) |
| Body mass index (kg/m²)                               | −0.033| 0.043 | 0.582  | 0.445   | 0.968 (0.890–1.052) |
| Duration of symptoms before treatment (months)        | −0.009| 0.005 | 3.481  | 0.062   | 0.991 (0.982–1.000) |
| **MEDICAL HISTORY**                                   |       |       |        |         |                  |
| Predisposing factors (yes vs. no)                     | −0.160| 0.234 | 0.465  | 0.495   | 0.852 (0.539–1.349) |
| Syncope (yes vs. no)                                  | −0.028| 0.22  | 0.016  | 0.900   | 0.973 (0.632–1.498) |
| Symptom scores before treatment (points)              | −0.001| 0.028 | 0.001  | 0.978   | 0.999 (0.946–1.055) |
| **PERSONAL HISTORY**                                  |       |       |        |         |                  |
| Motion sickness (yes vs. no)                          | 0.387 | 0.317 | 1.488  | 0.223   | 1.472 (0.791–2.739) |
| Allergic diseases (yes vs. no)                        | −0.198| 0.25  | 0.625  | 0.429   | 0.821 (0.503–1.340) |
| Family history about OI (yes vs. no)                  | 0.11  | 0.253 | 0.191  | 0.662   | 1.117 (0.681–1.832) |
| **CHARACTERISTICS IN STANDING-UP TEST**               |       |       |        |         |                  |
| Supine heart rate (bpm)                               | 0.025 | 0.011 | 5.703  | 0.017   | 1.026 (1.005–1.047) |
| Maximum upright heart rate (bpm)                      | 0.014 | 0.008 | 3.153  | 0.076   | 1.014 (0.999–1.030) |
| Changes of heart rate (bpm)                           | −0.001| 0.011 | 0.004  | 0.952   | 0.999 (0.977–1.022) |
| **ITEMS OF BLOOD ROUTINE TEST**                       |       |       |        |         |                  |
| Mean corpuscular hemoglobin concentration (g/L)       | 0.011 | 0.009 | 1.437  | 0.231   | 1.011 (0.993–1.029) |
| Platelet (10⁹/L)                                      | 0.002 | 0.002 | 0.757  | 0.384   | 1.002 (0.998–1.006) |
| 24 h urinary sodium excretion (mmol/24 h)             | −0.001| 0.002 | 0.218  | 0.641   | 0.999 (0.995–1.003) |
| Duration of treatment (months)                        | −0.001| 0.106 | −0.001 | 0.989   | 0.999 (0.812–1.228) |

OI, orthostatic intolerance.
independent indicators for the long-term outcomes for their unrepresentativeness of both blood volume and autonomic nervous function. Additionally, allergic diseases, common comorbidities in pediatric POTS patients (29, 30), and inheritance were not testified as independent factors.

Exactly, some limitations existed in the present study: (1) there is no control group in the present study. We could not tell the differences among patients receiving conventional interventions, pharmacological therapies and nothing; (2) there is a possibility of bias for the retrospective study design; (3) the study have the limitation of generalizability to other study populations for the characteristics, such as the similar gender ratio of the subjects in our study; and (4) the hazard ratios of the duration of symptoms before treatment and the maximum upright heart rate in the standing-up test were close to one.

To interpret the results of this study cautiously, the data showed that the cumulative symptom-free rate of POTS patients receiving conventional treatment would increase gradually over time and implementing conventional interventions to POTS patients with obvious tachycardia as early as possible might be of great help in improving their long-term outcomes.

**DATA AVAILABILITY**

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

**REFERENCES**

1. Jones PK, Shaw BH, Raj SR. Clinical challenges in the diagnosis and management of postural tachycardia syndrome. *Pract Neurol.* (2016) 16:431–8. doi: 10.1136/practneurol-2016-011405
2. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. *JAMA.* (1995) 274:961–7. doi: 10.1001/jama.274.12.961
3. Lin J, Han Z, Li X, Ochs T, Zhao J, Zhang X, et al. Risk factors for postural tachycardia syndrome in children and adolescents. *PLoS ONE.* (2014) 9:e113625. doi: 10.1371/journal.pone.0113625
4. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA. Quality of life in patients with postural tachycardia syndrome. *Mayo Clin Proc.* (2007) 82:308–13. doi: 10.4065/82.3.308
5. Raj V, Haman KL, Raj SR, Byrne D, Blakely RD, Biaggioni I, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. *J Neurol Neurosurg Psychiat.* (2009) 80:339–44. doi: 10.1136/jnnp.2008.144360
6. Johnson JN, Mack KJ, Kuntz NL, Brands CK, Porter CJ, Fischer PR. Postural orthostatic tachycardia syndrome: a clinical review. *Pediatr Neurol.* (2010) 42:77–85. doi: 10.1016/j.pediatrneurol.2009.07.002
7. Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vermin S, et al. Postural orthostatic tachycardia syndrome: the Mayo clinical experience. *Mayo Clin Proc.* (2007) 82:308–13. doi: 10.4065/82.3.308
8. Ruizieh M, Grubb BP. Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment. *Herschrittmacherther Elektrophysiol.* (2018) 29:183–6. doi: 10.1007/s00399-018-0563-1
9. Zhang Q, Liao Y, Tang C, Du J, Jin H. Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. *J Pediatr.* (2015) 161:281–4. doi: 10.1016/j.jpeds.2012.01.054
10. Lin J, Liu P, Wang Y, Li H, Li X, Zhao J, et al. Evaluation of the changes in heart rate during head-up test predicting the efficacy of oral rehydration salts on postural tachycardia syndrome in children. *Chin J Pediatr.* (2015) 53:25–9. doi: 10.3760/cma.j.issn.0578-1310.2015.01.005
11. Li H, Liao Y, Wang Y, Liu P, Sun C, Chen Y, et al. Baroreflex sensitivity predicts short-term outcome of postural tachycardia syndrome in children. *PLoS ONE.* (2016) 11:e0167525. doi: 10.1371/journal.pone.0167525
12. Li H, Wang Y, Liu P, Chen Y, Feng X, Tang C, et al. Body mass index (BMI) is associated with the therapeutic response to oral rehydration solution in children with postural tachycardia syndrome. *Pediatr Cardiol.* (2016) 37:1318–3. doi: 10.1007/s00246-016-1436-1

**ETHICS STATEMENT**

This research was authorized by the Ethics Committee of Peking University First Hospital and all guardians of included patients gave written informed consent in accordance with the percepts expressed in the Declaration of Helsinki.

**AUTHOR CONTRIBUTIONS**

CyT had primary responsibility for the protocol development, patient enrollment, data collecting, preliminary data analysis, and writing the manuscript. WL, JL, and HL assisted with data collecting and preliminary data analysis. XL gave important advice on study design and revised data analysis. CSiT gave important advice on the subject and revised the manuscript. JD and HF supervised the design and execution of the study, checked the data analysis, contributed to the writing of the manuscript, and had a final approval of the manuscript submitted. All authors have read and approved the final manuscript and assumed full responsibility for its contents.

**ACKNOWLEDGMENTS**

The authors thank the children and their parents who participated in this study. This study was supported by Science and Technology Program of Beijing (Z171100001017253), Peking University Clinical Scientist Program (BMU2019LCKXJ001, Beijing, China) and the Fundamental Research Funds for the Central Universities.
13. Lu W, Yan H, Wu S, Xu W, Jin H, Du J. Hemocytometric measures predict the efficacy of oral rehydration for children with postural tachycardia syndrome. *J Pediatr.* (2017) 187:220–4. doi: 10.1016/j.jpeds.2017.04.034

14. Lu W, Yan H, Wu S, Chen S, Xu W, Jin H, et al. Electrocardiography-derived predictors for therapeutic response to treatment in children with postural tachycardia syndrome. *J Pediatr.* (2016) 176:128–33. doi: 10.1016/j.jpeds.2016.05.030

15. Chen SL, Dahl C, Meyer HE, Madar AA. Estimation of salt intake assessed by 24-hour urinary sodium excretion among Somali adults in Oslo, Norway. *Nutrients.* (2018) 10:E900. doi: 10.3390/nu10070900

16. Wang C, Li Y, Liao Y, Tian H, Huang M, Dong X, et al. Chinese Pediatric Cardiology Society (CPCS) guideline for diagnosis and treatment of syncope in children and adolescents. *Sci Bull.* (2018) 63:1558–64. doi: 10.1016/j.scbh.2018.09.019

17. Tao C, Chen S, Li H, Wang Y, Wang Y, Liu P, et al. Value of immediate heart rate alteration from supine to upright in differential diagnosis between vasovagal syncope and postural tachycardia syndrome in children. *Front Pediatr.* (2018) 6:343. doi: 10.3389/fped.2018.00343

18. Tao C, Li X, Tang C, Jin H, Du J. Acceleration index predicts efficacy of orthostatic training on vasovagal syncope in children. *J Pediatr.* (2018) 207:54–8. doi: 10.1016/j.jpeds.2018.10.063

19. Pederson CL, Brook JB. Health-related quality of life and suicide risk in postural tachycardia syndrome. *Clin Auton Res.* (2017) 27:75–81. doi: 10.1007/s10286-017-0399-5

20. Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. *Mayo Clin Proc.* (2012) 87:746–52. doi: 10.1016/j.mayocp.2012.02.020

21. Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. *Mayo Clin Proc.* (2012) 87:746–52. doi: 10.1016/j.mayocp.2012.02.020

22. Stiles LE, Cinnamon J, Balan I. The patient perspective: what postural orthostatic tachycardia syndrome patients want physicians to know. *Auton Neurosci.* (2018) 215:3–11. doi: 10.1016/j.autneu.2018.02.005

23. Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome—diagnosis, physiology, and prognosis. *Auton Neurosci.* (2018) 215:3–11. doi: 10.1016/j.autneu.2018.02.005

24. Medow MS, Stewart JM. The postural tachycardia syndrome. *Cardiol Rev.* (2007) 15:67–75. doi: 10.1097/01.crd.0000233768.68421.40

25. Lin J, Jin H, Du J. Assessment of therapeutic biomarkers in the treatment of children with postural tachycardia syndrome and vasovagal syncope. *Cardiol Young.* (2014) 24:792–6. doi: 10.1017/S1047951114000316

26. Endo Y, Yamauchi K, Tsutsui Y, Ishihara Z, Yamazaki F, Sagawa S, et al. Changes in blood pressure and muscle sympathetic nerve activity during water drinking in humans. *Jpn J Physiol.* (2002) 52:421–7. doi: 10.2170/jjophysiol.52.421

27. Tan MP, Newton JL, Chadwick TJ, Gray JC, Nath S, Parry SW. Home orthostatic training in vasovagal syncope modifies autonomic tone: results of a randomized, placebo-controlled pilot study. *Euroacep.* (2010) 12:240–6. doi: 10.1093/europace/eup368

28. Oxzemir O, Soylu M, Alyn O, Geyik B, Demir AD, Aras D, et al. Association between mean platelet volume and autonomic nervous system functions: Increased mean platelet volume reflects sympathetic overactivity. *Exp Clin Cardiol.* (2004) 9:243–7. doi: 10.1111/j.1542-474X.2004.94575.x

29. Liao Y, Zhang Q, Li H, Wang Y, Liu P, Du J, et al. Co-morbidity of vasovagal syncope and postural tachycardia syndrome with allergic diseases in children. *J Peking Univ Health Sci.* (2017) 49:783–8. doi: 10.3969/j.issn.1671-167X.2017.05.007

30. Penny HA, Aziz I, Ferrar M, Atkinson J, Hoggard N, Hadjivassiliou M, et al. Is there a relationship between gluten sensitivity and postural tachycardia syndrome? *Eur J Gastroenterol Hepatol.* (2016) 28:1383–7. doi: 10.1097/MEG.0000000000000740

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.